1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
CONMED Corporation

CONMED Corporation

CNMD
CONMED CorporationUS flagNew York Stock Exchange
49.32
USD
-0.10
- -
1.48BMarket Cap
CONMED Corporation
CNMD
(New York Stock Exchange)

Recent

price

49.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
24.86
25.67
27.11
27.51
27.01
26.01
27.46
28.5
30.57
33.72
30.18
34.66
34.8
40.59
42.37
44.29
44.76
Revenue per Share
1.06
0.03
1.43
1.3
1.17
1.1
0.53
1.99
1.45
1.01
0.33
2.14
-2.68
2.1
4.29
1.52
1.84
Basic EPS, GAAP
0.82
3.02
2.6
2.25
1.82
1.3
0.9
1.89
2.07
2.65
1.8
3.32
0.39
3.47
4.99
4.86
4.39
Free Cash Flow per Basic Share
- -
- -
0.45
0.6
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.4
Dividend per Share
20.78
20.51
21.39
21.98
21.1
21.12
20.86
22.58
23.54
25
24.54
26.74
24.45
27.12
31.15
33.36
34.55
Book Value per Share
3.59
5.11
0.86
1.39
0.31
0.59
-8.5
-6.63
-5.38
-15.49
-14.22
-10.32
-24.66
-20.22
-14.9
-11.49
-10.61
Tangible Book Value per Share
29
28
28
28
27
28
28
28
28
28
29
29
30
31
31
31
31
Basic Weighted Avg Shares
714
725
767
763
740
719
764
796
860
955
862
1,011
1,045
1,245
1,307
1,375
1,372
Sales/Revenue/Turnover
8
9.46
8.86
7.41
7.13
7.12
4.93
5.89
8.29
8.28
5.33
10.86
6.7
9.69
15.33
7.46
8.04
Operating Margin (%)
38
39
47
48
46
44
55
58
61
72
73
71
70
72
72
74
75
Depreciation Expense
30
1
40
36
32
30
15
55
41
29
10
63
-81
64
132
47
56
Net Income, GAAP
33.53
- -
31.94
29.02
31.03
32.44
24.31
- -
19.35
8.34
- -
14.45
- -
20.25
18.77
33.83
32.12
Effective Tax Rate (%)
4.25
0.1
5.28
4.71
4.35
4.24
1.92
6.97
4.75
3
1.1
6.19
-7.71
5.18
10.13
3.42
4.12
Profit Margin (%)
170
226
224
261
265
240
217
207
213
209
226
263
285
305
362
358
220
Working Capital
85
89
161
214
240
269
488
472
439
772
735
672
985
973
905
834
657
LT Debt
587
573
607
606
581
585
581
631
662
710
709
785
746
834
963
1,033
1,041
Total Equity
4.92
- -
6.2
5.04
4.42
4.11
2.95
- -
5.15
5.54
- -
6.42
- -
5.35
8.88
3.65
3.98
Return on Invested Capital (%)
4.91
- -
5.98
5.02
4.43
4.12
2.72
- -
5.14
5.17
- -
6.34
- -
5.33
8.85
3.62
4.09
Return on Capital (%)
5.22
0.13
6.86
5.92
5.42
5.23
2.52
9.16
6.32
4.17
1.34
8.37
-10.53
8.16
14.74
4.72
5.53
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
177
LT Borrowings
834
860
657
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
30
30
Market Capitalization
1,257
1,066
987

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
673
671
676
Cash, Cash Equivalents & STI
41
35
37
Accounts Receivable, Net
248
229
240
Inventories
356
366
360
Total Current Liabilities
315
293
455
Payables & Accruals
94
105
101
ST Debt
1
1
177
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.02%
8.06%
7.31%
Free Cash Flow
94.87%
172.19%
-1.95%
Net Income, GAAP
29.27%
37.86%
-64.47%
Sales/Revenue/Turnover
6.97%
9.97%
5.18%
Total Cash Common Dividend
1.14%
1.64%
0.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
312
332
317
346
1,307
2025
321
342
338
373
1,375
2026
317
343
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.64
0.97
1.59
1.09
4.29
2025
0.19
0.69
0.09
0.54
1.52
2026
0.45
0.77
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.2
0.2
0.2
0.8
2025
0.2
0.2
0.2
0.2
0.8
2026
- -
- -
- -
- -
- -
Similar Companies
Codex DNA, Inc. (DNAY)
Neovasc Inc. (NVCN.TO)
RetinalGenix Technologies Inc. (RTGN)
Nu-Med Plus, Inc. (NUMD)
Deltex Medical Group plc (DTXMF)
HeraMED Limited (HMD.AX)
Business
CONMED Corporation (NYSE: CNMD) develops, manufactures, and markets surgical devices and supplies for use in minimally invasive procedures and orthopedics worldwide. The company offers a broad portfolio of products including powered instruments such as the Buffalo Filter and HiClear Oscillating Saw; orthopedic implants and biologics under brands like BioBrace and CrossFix; endoscopy devices including the DuraClip and OneSnip; general surgery instruments like the Repose Retractor System; and patient positioners such as the Plastech Gel products. CONMED operates through two primary segments—Orthopedic Surgery and General Surgery—serving hospitals, ambulatory surgery centers, and outpatient clinics primarily in the United States, Europe, and Asia-Pacific. Founded in 1970 and headquartered in Largo, Florida, the company maintains manufacturing facilities in the U.S., Mexico, and Poland. In recent developments, CONMED completed the acquisition of In2Bones Global, Inc. in March 2024, expanding its upper extremity orthopedic portfolio with innovative implants and instrumentation; launched the next-generation AirSeal iGS system in 2024 to enhance laparoscopic procedures; and reported strong revenue growth in its orthopedic segment during 2025, driven by strategic investments in sports medicine and trauma solutions.[web:previous]

Company News

Company News APIChatGPT

  • defenseworld.net

    Canada Pension Plan Investment Board Buys Shares of 13,800 CONMED Corporation $CNMD

  • zacks.com

    Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?

  • businesswire.com

    CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

  • seekingalpha.com

    CONMED Corporation: Organic Growth Is Masked By Divestitures

  • zacks.com

    CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last

  • zacks.com

    Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?

  • zacks.com

    Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?

  • zacks.com

    Here's Why You Should Retain CONMED Stock in Your Portfolio Now

  • defenseworld.net

    California State Teachers Retirement System Raises Stock Holdings in CONMED Corporation $CNMD

  • defenseworld.net

    Arrowstreet Capital Limited Partnership Purchases 287,150 Shares of CONMED Corporation $CNMD

  • zacks.com

    CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands

  • seekingalpha.com

    CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    CONMED Q2 Earnings Call Highlights

  • zacks.com

    Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say

  • zacks.com

    Conmed (CNMD) Q2 Earnings and Revenues Top Estimates

  • businesswire.com

    CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

  • zacks.com

    CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula

  • gurufocus.com

    CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula

  • businesswire.com

    CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula

  • defenseworld.net

    Bessemer Group Inc. Purchases 36,940 Shares of CONMED Corporation $CNMD